alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Home › Research › Topics › antibodies-targeting

antibodies-targeting

2 studies tagged antibodies-targeting, dated 2022-02-14 to 2023-09-14. Bibliography: BibTeX (.bib) · RIS (.ris)

Newest in this topic

  1. Anti-tau antibodies targeting a conformation-dependent epitope selectively bind seeds 2023-09-14
  2. Delivery of Intravenously Administered Antibodies Targeting Alzheimer's Disease-Relevant Tau Species into the Brain Based on Receptor-Mediated Transcytosis 2022-02-14

Studies

2 studies carry this tag.

Date range

2022 to 2023

Top journals

  • Pharmaceutics 1
  • The Journal of biological chemistry 1

Newest first, then by address. Each study has a usefulness score out of 100 (rubric version 4.0); tap a score to see what makes it up. Tags were assigned automatically from each study's title and summary. The same studies as a filter in the library.

  1. Anti-tau antibodies targeting a conformation-dependent epitope selectively bind seeds

    ✓ Peer-reviewed alzhub usefulness score 43 out of 100. The Journal of biological chemistry 2023-09-14 Drug development

    Neurodegenerative tauopathies are caused by the transition of tau protein from a monomer to a toxic aggregate.

  2. Delivery of Intravenously Administered Antibodies Targeting Alzheimer's Disease-Relevant Tau Species into the Brain Based on Receptor-Mediated Transcytosis

    ✓ Peer-reviewed alzhub usefulness score 43 out of 100. Pharmaceutics 2022-02-14 Drug development

    Alzheimer's disease (AD) is a neurodegenerative disease that causes memory loss, cognitive decline, and eventually dementia.

All topic tags with their study counts